Long-term follow-up of late morbidity, cosmetic outcome and body image after breast conserving therapy. A study from the Danish Breast Cancer Cooperative Group (DBCG)

Acta Oncologica

Volumn 52, Issue 2, 2013, Pages 259-269

  Lyngholm, Christina D ^a   Christiansen, Peer M ^a   Damsgaard, Tine E ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; TAMOXIFEN; COSMETIC; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARM EDEMA; BODY IMAGE; BREAST; BREAST CANCER; BREAST FIBROSIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EXAMINATION; CLOTHING; CONFERENCE PAPER; DENMARK; DISEASE ASSOCIATION; DISEASE SEVERITY; ESTHETICS; FEMALE; FEMINISM; FOLLOW UP; HABIT; HEMATOMA; HUMAN; INTERVIEW; LONG TERM CARE; MAJOR CLINICAL STUDY; MORBIDITY; ORGAN SIZE; PARTIAL MASTECTOMY; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCAR; SELF REPORT; SEXUAL BEHAVIOR; SMOKING; TREATMENT OUTCOME; TUMOR VOLUME; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OUTCOME VARIABLE;

ADULT; AGED; AGED, 80 AND OVER; BODY IMAGE; BREAST NEOPLASMS; COOPERATIVE BEHAVIOR; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MORBIDITY; RECONSTRUCTIVE SURGICAL PROCEDURES; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872583523     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.744469     Document Type: Conference Paper

References (32)

1. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. Danish Breast Cancer Cooperative Group. JNatl Cancer Inst Monogr 1992; 19-25.
2. Jacobson JA, Danforth DN, Cowan KH, d 'Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of acomparison of conservation with mastectomy in the treatment of stage Iand II breast cancer. NEngl JMed 1995; 332: 907-11.
3. van TG, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur JCancer 1999; 35: 32-8.
4. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-fi ve-year follow-up of arandomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. NEngl JMed 2002; 347: 567-75.
5. Blichert-Toft M, Nielsen M, During M, Moller S, Rank F, Overgaard M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008; 47:672-81.
6. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-106.
7. Ewertz M, Kempel MM, During M, Jensen MB, Andersson M, Christiansen P, et al. Breast conserving treatment in Denmark, 1989-1998. Anationwide population-based study of the Danish Breast Cancer Co-operative Group. Acta Oncol 2008; 47: 682-90.
8. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008; 47: 506-24.
9. DBCG-89 protocol [Danish Breast Cancer Cooperative Group], 2012. [cited 2012 June 25]. Available from: http://dbcg.dk/PDF%20Filer/DBCG%2089%20protokol. pdf
10. Overgaard M, Christensen JJ. Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experience. Acta Oncol 2008; 47: 639-53.
11. Ejlertsen B, Mouridsen HT, Jensen MB. Adjuvant cyclophosphamide, methotrexate, and fl uorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta Oncol 2008; 47: 662-71.
12. Pezner RD, Patterson MP, Hill LR, Vora N, Desai KR, Archambeau JO, et al. Breast retraction assessment: An objective evaluation of cosmetic results of patients treated conservatively for breast cancer. Int JRadiat Oncol Biol Phys 1985; 11: 575-8.
13. Cardoso JS, Cardoso MJ. Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment. Artif Intell Med 2007; 40: 115-26.
14. Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M, et al. Cosmetic outcome and breast morbidity in breast-conserving treatment-results from the Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol 2002; 41: 369-80.
15. Whitley E, Ball J. Statistics review 4: Sample size calculations. Crit Care 2002; 6: 335-41.
16. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, et al. Predictors of the risk of fi brosis at 10 years after breast conserving therapy for early breast cancer: Astudy based on the EORTC Trial 22881-10882 ' boost versus no boost '. Eur JCancer 2008; 44: 2587-99.
17. Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, et al. The addition of aboost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. Asummary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother 2008; 12: 565-70.
18. Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on cosmetic outcome and late normaltissue reactions after breast conservation. Acta Oncol 2007; 46: 525-33.
19. Curran D, van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: Results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur JCancer 1998; 34: 307-14.
20. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. NEngl JMed 2010; 362: 513-20.
21. Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW. Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int JRadiat Oncol Biol Phys 2006; 64: 489-95.
22. Wazer DE, Morr J, Erban JK, Schmid CH, Ruthazer R, Schmidt-Ullrich RK. The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Cancer 1997; 80: 732-40.
23. Clarke D, Martinez A, Cox RS. Analysis of cosmetic results and complications in patients with stage Iand II breast cancer treated by biopsy and irradiation. Int JRadiat Oncol Biol Phys 1983; 9: 1807-13.
24. Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 2011; 50: 187-93.
25. Hvilsom GB, Holmich LR, Frederiksen K, Steding-Jessen M, Friis S, Dalton SO. Socioeconomic position and breast reconstruction in Danish women. Acta Oncol 2011; 50: 265-73.
26. Dundas KL, Atyeo J, Cox J. What is alarge breast? Measuring and categorizing breast size for tangential breast radiation therapy. Australas Radiol 2007; 51: 589-93.
27. Strombeck JO, Malm M. Priority grouping in awaiting list of patients for reduction mammaplasty. Ann Plast Surg 1986; 17: 498-502.
28. Ringberg A, Bageman E, Rose C, Ingvar C, Jernstrom H. Of cup and bra size: Reply to aprospective study of breast size and premenopausal breast cancer incidence. Int JCancer 2006; 119: 2242-3.
29. Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003; 69: 127-35.
30. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profi les? Acta Oncol 2005; 44: 801-15.
31. Andreassen CN, Alsner J, Overgaard M, Sorensen FB, Overgaard J. Risk of radiation-induced subcutaneous fi brosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM- A study based on DNA from formalin fi xed paraffi nembedded tissue samples. Int JRadiat Biol 2006; 82: 577-86.
32. Alsner J, Rodningen OK, Overgaard J. Differential gene expression before and after ionizing radiation of subcutaneous fi broblasts identifi es breast cancer patients resistant to radiation-induced fi brosis. Radiother Oncol 2007; 83: 261-6.